Peter A. Foley

St Vincent's Hospital Melbourne
Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 128 publications

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Journal: Acta dermato-venereologica
Published: July 16, 2026

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Journal: Acta dermato-venereologica
Published: July 16, 2026

Could an Essential Medicines List Strengthen Access and Equity in Australian Dermatology?

Could an Essential Medicines List Strengthen Access and Equity in Australian Dermatology?

Journal: The Australasian journal of dermatology
Published: April 09, 2026

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.

Journal: Dermatology and therapy
Published: April 02, 2026

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

Journal: Dermatology and therapy
Published: March 08, 2026

Waiting for Access: How Bureaucracy Blocks Innovation in Australian Dermatology.

Waiting for Access: How Bureaucracy Blocks Innovation in Australian Dermatology.

Journal: The Australasian journal of dermatology
Published: November 15, 2025

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review.

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review.

Journal: The Australasian journal of dermatology
Published: October 09, 2025

Is the Future Oral? Towards Sustainable and Patient-Centered Biologic Treatment in Dermatology.

Is the Future Oral? Towards Sustainable and Patient-Centered Biologic Treatment in Dermatology.

Journal: The Australasian journal of dermatology
Published: October 07, 2025

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial.

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial.

Journal: The British journal of dermatology
Published: September 24, 2025

Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.

Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.

Journal: Immunotherapy
Published: September 01, 2025

The role of biosimilars in enhancing global access to psoriasis treatment.

The role of biosimilars in enhancing global access to psoriasis treatment.

Journal: The Journal of investigative dermatology
Published: July 06, 2025

Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study.

Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 30, 2025
Showing 1-12 of 128

Last Updated: 09/26/2026